Article Text

Download PDFPDF

EPV100/#181 Uterine carcinosarcoma: a multicentre review of treatment and outcomes over 26 years
  1. C Yim1,
  2. S-E Yao2,
  3. J Phung3,
  4. M Davies-Tuck4,
  5. T Manolitsas2,
  6. J Mcneilage2,
  7. K Reid2,
  8. O Mcnally5,
  9. R Rome6 and
  10. T Jobling2
  1. 1Royal Women’s Hospital, Gynaecologic Cancer Centre, Randwick, Australia
  2. 2Monash Health, Gynaeoncology Unit, Moorabbin, Australia
  3. 3University of Newcastle, School of Medicine and Public Health, Newcastle University, Australia
  4. 4Hudson Institute of Medical Research, Epidemiology and Clinical Trials, Clayton, Australia
  5. 5Royal Women’s Hospital, Gynaeoncology Unit, Parkville, Australia
  6. 6Epworth Healthcare, Epworth Freemasons Hospital, East Melbourne, Australia


Objectives Uterine carcinosarcoma (UCS) is a rare neoplasm with a poor prognosis and a paucity of evidence on treatment. The objective was to review the characteristics, treatment and outcomes of UCS cases across two gynaeoncology units and five private gynaeoncology practices in Melbourne.

Methods UCS cases were identified from hysterectomy pathology records between 1994 and 2020 inclusive. Patient characteristics, histopathological stage, adjuvant therapy, recurrence and survival status were extracted from patient records.

Results 208 cases of UCS were identified. The overall recurrence rate was 26.0% and the overall death rate was 60.1%. Increasing age at diagnosis was associated with an increased risk of death (adjusted OR 1.04, 95% CI 1.01–1.08, p=0.019). Risk of death was highest in Stage III disease (adjusted OR 4.37, 95% CI 1.67–11.40). Recurrence was a strong determinant of death, with an adjusted OR of 7.58 (p<0.001).

Conclusions In this relatively large homogenous cohort of UCS cases, significant predictors for survival included age at diagnosis, stage of disease and recurrence.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.